SK Life Science, Inc.

SK Life Science, Inc. is focused on developing treatments for CNS disorders.

We have a pipeline of eight compounds in development. The first approved drug is XCOPRI, an anti-epileptic drug indicated for focal seizures in adult patients.

For more information on XCOPRI or SK life science, visit www.XCOPRIhcp.com or www.SKLifeScienceInc.com

Pharmaceutical